Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high‐risk for hepatocellular carcinoma
BACKGROUND. The objective of this study was to examine the usefulness of platelet counts in the diagnosis of cirrhosis and for identifying high‐risk individuals in a community‐based hepatocellular carcinoma (HCC) screening program. METHODS. Pilot Study 1 determined the correlation between platelet c...
Gespeichert in:
| Veröffentlicht in: | Cancer 2006-11, Vol.107 (9), p.2212-2222 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2222 |
|---|---|
| container_issue | 9 |
| container_start_page | 2212 |
| container_title | Cancer |
| container_volume | 107 |
| creator | Lu, Sheng‐Nan Wang, Jing‐Houng Liu, Shiann‐Long Hung, Chao‐Hung Chen, Chien‐Hung Tung, Hung‐Da Chen, Tsung‐Ming Huang, Wu‐Shiung Lee, Chuan‐Mo Chen, Chia‐Cheng Changchien, Chi‐Sin |
| description | BACKGROUND.
The objective of this study was to examine the usefulness of platelet counts in the diagnosis of cirrhosis and for identifying high‐risk individuals in a community‐based hepatocellular carcinoma (HCC) screening program.
METHODS.
Pilot Study 1 determined the correlation between platelet counts and pathologic hepatic fibrosis scores among individuals with chronic hepatitis B virus (HBV) infection (n = 122 patients) and hepatitis C virus (HCV) infection (n = 244 patients). Pilot Study 2 investigated proportions of individuals with thrombocytopenia ( |
| doi_str_mv | 10.1002/cncr.22242 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69007224</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69007224</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4592-4ea254c55039dfe05fd73e696c80aa9f5b32f671bd0f1ea473fe9cbb207790293</originalsourceid><addsrcrecordid>eNp9kM9O3DAQxq0KVBbaSx-g8qU9IIXaThyvj9WKAtIKJESl3qKJMyYuSby1E6G9ceXGM_Ik9f6RuHGyPd_P38x8hHzh7IwzJn6YwYQzIUQhPpAZZ1pljBfigMwYY_NMFvmfI3Ic49_0VELmH8kRV4xrlc9n5PmuDb6vvVmPfoWDAwqRAo1TCP4eRqTWB2pcCK2PLilDk9QewgOGrTS2SF2Dw-isMzA6P1Bv6SrdUi3xI23dffv69BJcfNj-aDGp3mDXTR0kbwjGDb6HT-TQQhfx8_48Ib9_nd8tLrPlzcXV4ucyM4XUIisQhCyMlCzXjUUmbaNyLHVp5gxAW1nnwpaK1w2zHKFQuUVt6lowpTQTOj8h33e-q-D_TRjHqndxMw4M6KdYlXoTkygSeLoDTfAxBrTVKri0-rrirNoEX22Cr7bBJ_jr3nWqe2ze0H3SCfi2ByAa6GyAwbj4xs2FlLJUieM77tF1uH6nZbW4Xtzumv8H0h6ewg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69007224</pqid></control><display><type>article</type><title>Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high‐risk for hepatocellular carcinoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Lu, Sheng‐Nan ; Wang, Jing‐Houng ; Liu, Shiann‐Long ; Hung, Chao‐Hung ; Chen, Chien‐Hung ; Tung, Hung‐Da ; Chen, Tsung‐Ming ; Huang, Wu‐Shiung ; Lee, Chuan‐Mo ; Chen, Chia‐Cheng ; Changchien, Chi‐Sin</creator><creatorcontrib>Lu, Sheng‐Nan ; Wang, Jing‐Houng ; Liu, Shiann‐Long ; Hung, Chao‐Hung ; Chen, Chien‐Hung ; Tung, Hung‐Da ; Chen, Tsung‐Ming ; Huang, Wu‐Shiung ; Lee, Chuan‐Mo ; Chen, Chia‐Cheng ; Changchien, Chi‐Sin</creatorcontrib><description>BACKGROUND.
The objective of this study was to examine the usefulness of platelet counts in the diagnosis of cirrhosis and for identifying high‐risk individuals in a community‐based hepatocellular carcinoma (HCC) screening program.
METHODS.
Pilot Study 1 determined the correlation between platelet counts and pathologic hepatic fibrosis scores among individuals with chronic hepatitis B virus (HBV) infection (n = 122 patients) and hepatitis C virus (HCV) infection (n = 244 patients). Pilot Study 2 investigated proportions of individuals with thrombocytopenia (<150 × 103/mm3) among patients with HCC (n = 4042 patients). Pilot Study 3 demonstrated the correlation between platelet counts and ultrasonographic (US) parenchyma scores among anti‐HCV‐positive individuals (n = 75 patients). The core study was a 2‐stage, community‐based screening for HCC among residents age 40 years or older in townships with a high prevalence of anti‐HCV (n = 4616 individuals) and in townships with a low prevalence of anti‐HCV (n = 1694 individuals). Patients with thrombocytopenia were identified for US and α‐fetoprotein screening.
RESULTS.
Among the individuals who were positive for anti‐HCV, platelet counts decreased according to increased pathologic fibrosis scores or US scores for liver parenchyma disease: The best cutoff platelet count was 150 × 103/mm3 for a diagnosis of cirrhosis. The sensitivity and specificity were 68.2% and 76.4%, respectively, for pathologic cirrhosis and 76.2% and 87.8%, respectively, for US cirrhosis. Forty‐eight percent of patients with HCC were thrombocytopenic. The proportion of thrombocytopenia was significantly greater in patients with HCV‐related HCC (63%) than in patients with HBV‐related HCC (42%). In the townships with high and low anti‐HCV prevalence, the prevalence of thrombocytopenia was 17.9% and 6.1%, respectively, (P < .001), respectively. Twenty‐five patients were diagnosed with HCC, and all of those patients resided in the high‐prevalence township.
CONCLUSIONS.
Thrombocytopenia was a valid surrogate of cirrhosis and a valid marker for the identification of individuals at high‐risk for HCC, especially in areas that had a high prevalence of HCV. Cancer 2006. © 2006 American Cancer Society.
Thrombocytopenia is a valid surrogate of cirrhosis and is a marker for the identification of high‐risk patients with hepatocellular carcinoma, especially in areas with prevalent high hepatitis C virus infection.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.22242</identifier><identifier>PMID: 17019738</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; Area Under Curve ; Biological and medical sciences ; Blood Platelets - pathology ; Carcinoma, Hepatocellular - diagnosis ; Carcinoma, Hepatocellular - epidemiology ; cirrhosis ; Community Health Services ; community screening ; Comorbidity ; Female ; Fibrosis - diagnosis ; Fibrosis - epidemiology ; Hematologic and hematopoietic diseases ; Hepatitis B - diagnosis ; Hepatitis B - epidemiology ; hepatitis B virus ; Hepatitis C - diagnosis ; Hepatitis C - epidemiology ; hepatitis C virus ; hepatocellular carcinoma ; Humans ; Liver Cirrhosis - diagnosis ; Liver Cirrhosis - epidemiology ; Liver Neoplasms - diagnosis ; Liver Neoplasms - epidemiology ; Male ; Mass Screening ; Medical sciences ; Middle Aged ; Pilot Projects ; platelet ; Platelet diseases and coagulopathies ; Predictive Value of Tests ; Prevalence ; Risk Factors ; Sensitivity and Specificity ; Survival Rate ; Taiwan - epidemiology ; Thrombocytopenia - diagnosis ; Thrombocytopenia - epidemiology ; Tumors ; ultrasonography ; α‐fetoprotein</subject><ispartof>Cancer, 2006-11, Vol.107 (9), p.2212-2222</ispartof><rights>Copyright © 2006 American Cancer Society</rights><rights>2006 INIST-CNRS</rights><rights>(c) 2006 American Cancer Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4592-4ea254c55039dfe05fd73e696c80aa9f5b32f671bd0f1ea473fe9cbb207790293</citedby><cites>FETCH-LOGICAL-c4592-4ea254c55039dfe05fd73e696c80aa9f5b32f671bd0f1ea473fe9cbb207790293</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.22242$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.22242$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,1432,27915,27916,45565,45566,46400,46824</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18255567$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17019738$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lu, Sheng‐Nan</creatorcontrib><creatorcontrib>Wang, Jing‐Houng</creatorcontrib><creatorcontrib>Liu, Shiann‐Long</creatorcontrib><creatorcontrib>Hung, Chao‐Hung</creatorcontrib><creatorcontrib>Chen, Chien‐Hung</creatorcontrib><creatorcontrib>Tung, Hung‐Da</creatorcontrib><creatorcontrib>Chen, Tsung‐Ming</creatorcontrib><creatorcontrib>Huang, Wu‐Shiung</creatorcontrib><creatorcontrib>Lee, Chuan‐Mo</creatorcontrib><creatorcontrib>Chen, Chia‐Cheng</creatorcontrib><creatorcontrib>Changchien, Chi‐Sin</creatorcontrib><title>Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high‐risk for hepatocellular carcinoma</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND.
The objective of this study was to examine the usefulness of platelet counts in the diagnosis of cirrhosis and for identifying high‐risk individuals in a community‐based hepatocellular carcinoma (HCC) screening program.
METHODS.
Pilot Study 1 determined the correlation between platelet counts and pathologic hepatic fibrosis scores among individuals with chronic hepatitis B virus (HBV) infection (n = 122 patients) and hepatitis C virus (HCV) infection (n = 244 patients). Pilot Study 2 investigated proportions of individuals with thrombocytopenia (<150 × 103/mm3) among patients with HCC (n = 4042 patients). Pilot Study 3 demonstrated the correlation between platelet counts and ultrasonographic (US) parenchyma scores among anti‐HCV‐positive individuals (n = 75 patients). The core study was a 2‐stage, community‐based screening for HCC among residents age 40 years or older in townships with a high prevalence of anti‐HCV (n = 4616 individuals) and in townships with a low prevalence of anti‐HCV (n = 1694 individuals). Patients with thrombocytopenia were identified for US and α‐fetoprotein screening.
RESULTS.
Among the individuals who were positive for anti‐HCV, platelet counts decreased according to increased pathologic fibrosis scores or US scores for liver parenchyma disease: The best cutoff platelet count was 150 × 103/mm3 for a diagnosis of cirrhosis. The sensitivity and specificity were 68.2% and 76.4%, respectively, for pathologic cirrhosis and 76.2% and 87.8%, respectively, for US cirrhosis. Forty‐eight percent of patients with HCC were thrombocytopenic. The proportion of thrombocytopenia was significantly greater in patients with HCV‐related HCC (63%) than in patients with HBV‐related HCC (42%). In the townships with high and low anti‐HCV prevalence, the prevalence of thrombocytopenia was 17.9% and 6.1%, respectively, (P < .001), respectively. Twenty‐five patients were diagnosed with HCC, and all of those patients resided in the high‐prevalence township.
CONCLUSIONS.
Thrombocytopenia was a valid surrogate of cirrhosis and a valid marker for the identification of individuals at high‐risk for HCC, especially in areas that had a high prevalence of HCV. Cancer 2006. © 2006 American Cancer Society.
Thrombocytopenia is a valid surrogate of cirrhosis and is a marker for the identification of high‐risk patients with hepatocellular carcinoma, especially in areas with prevalent high hepatitis C virus infection.</description><subject>Adult</subject><subject>Aged</subject><subject>Area Under Curve</subject><subject>Biological and medical sciences</subject><subject>Blood Platelets - pathology</subject><subject>Carcinoma, Hepatocellular - diagnosis</subject><subject>Carcinoma, Hepatocellular - epidemiology</subject><subject>cirrhosis</subject><subject>Community Health Services</subject><subject>community screening</subject><subject>Comorbidity</subject><subject>Female</subject><subject>Fibrosis - diagnosis</subject><subject>Fibrosis - epidemiology</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hepatitis B - diagnosis</subject><subject>Hepatitis B - epidemiology</subject><subject>hepatitis B virus</subject><subject>Hepatitis C - diagnosis</subject><subject>Hepatitis C - epidemiology</subject><subject>hepatitis C virus</subject><subject>hepatocellular carcinoma</subject><subject>Humans</subject><subject>Liver Cirrhosis - diagnosis</subject><subject>Liver Cirrhosis - epidemiology</subject><subject>Liver Neoplasms - diagnosis</subject><subject>Liver Neoplasms - epidemiology</subject><subject>Male</subject><subject>Mass Screening</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pilot Projects</subject><subject>platelet</subject><subject>Platelet diseases and coagulopathies</subject><subject>Predictive Value of Tests</subject><subject>Prevalence</subject><subject>Risk Factors</subject><subject>Sensitivity and Specificity</subject><subject>Survival Rate</subject><subject>Taiwan - epidemiology</subject><subject>Thrombocytopenia - diagnosis</subject><subject>Thrombocytopenia - epidemiology</subject><subject>Tumors</subject><subject>ultrasonography</subject><subject>α‐fetoprotein</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM9O3DAQxq0KVBbaSx-g8qU9IIXaThyvj9WKAtIKJESl3qKJMyYuSby1E6G9ceXGM_Ik9f6RuHGyPd_P38x8hHzh7IwzJn6YwYQzIUQhPpAZZ1pljBfigMwYY_NMFvmfI3Ic49_0VELmH8kRV4xrlc9n5PmuDb6vvVmPfoWDAwqRAo1TCP4eRqTWB2pcCK2PLilDk9QewgOGrTS2SF2Dw-isMzA6P1Bv6SrdUi3xI23dffv69BJcfNj-aDGp3mDXTR0kbwjGDb6HT-TQQhfx8_48Ib9_nd8tLrPlzcXV4ucyM4XUIisQhCyMlCzXjUUmbaNyLHVp5gxAW1nnwpaK1w2zHKFQuUVt6lowpTQTOj8h33e-q-D_TRjHqndxMw4M6KdYlXoTkygSeLoDTfAxBrTVKri0-rrirNoEX22Cr7bBJ_jr3nWqe2ze0H3SCfi2ByAa6GyAwbj4xs2FlLJUieM77tF1uH6nZbW4Xtzumv8H0h6ewg</recordid><startdate>20061101</startdate><enddate>20061101</enddate><creator>Lu, Sheng‐Nan</creator><creator>Wang, Jing‐Houng</creator><creator>Liu, Shiann‐Long</creator><creator>Hung, Chao‐Hung</creator><creator>Chen, Chien‐Hung</creator><creator>Tung, Hung‐Da</creator><creator>Chen, Tsung‐Ming</creator><creator>Huang, Wu‐Shiung</creator><creator>Lee, Chuan‐Mo</creator><creator>Chen, Chia‐Cheng</creator><creator>Changchien, Chi‐Sin</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20061101</creationdate><title>Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high‐risk for hepatocellular carcinoma</title><author>Lu, Sheng‐Nan ; Wang, Jing‐Houng ; Liu, Shiann‐Long ; Hung, Chao‐Hung ; Chen, Chien‐Hung ; Tung, Hung‐Da ; Chen, Tsung‐Ming ; Huang, Wu‐Shiung ; Lee, Chuan‐Mo ; Chen, Chia‐Cheng ; Changchien, Chi‐Sin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4592-4ea254c55039dfe05fd73e696c80aa9f5b32f671bd0f1ea473fe9cbb207790293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Area Under Curve</topic><topic>Biological and medical sciences</topic><topic>Blood Platelets - pathology</topic><topic>Carcinoma, Hepatocellular - diagnosis</topic><topic>Carcinoma, Hepatocellular - epidemiology</topic><topic>cirrhosis</topic><topic>Community Health Services</topic><topic>community screening</topic><topic>Comorbidity</topic><topic>Female</topic><topic>Fibrosis - diagnosis</topic><topic>Fibrosis - epidemiology</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hepatitis B - diagnosis</topic><topic>Hepatitis B - epidemiology</topic><topic>hepatitis B virus</topic><topic>Hepatitis C - diagnosis</topic><topic>Hepatitis C - epidemiology</topic><topic>hepatitis C virus</topic><topic>hepatocellular carcinoma</topic><topic>Humans</topic><topic>Liver Cirrhosis - diagnosis</topic><topic>Liver Cirrhosis - epidemiology</topic><topic>Liver Neoplasms - diagnosis</topic><topic>Liver Neoplasms - epidemiology</topic><topic>Male</topic><topic>Mass Screening</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pilot Projects</topic><topic>platelet</topic><topic>Platelet diseases and coagulopathies</topic><topic>Predictive Value of Tests</topic><topic>Prevalence</topic><topic>Risk Factors</topic><topic>Sensitivity and Specificity</topic><topic>Survival Rate</topic><topic>Taiwan - epidemiology</topic><topic>Thrombocytopenia - diagnosis</topic><topic>Thrombocytopenia - epidemiology</topic><topic>Tumors</topic><topic>ultrasonography</topic><topic>α‐fetoprotein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lu, Sheng‐Nan</creatorcontrib><creatorcontrib>Wang, Jing‐Houng</creatorcontrib><creatorcontrib>Liu, Shiann‐Long</creatorcontrib><creatorcontrib>Hung, Chao‐Hung</creatorcontrib><creatorcontrib>Chen, Chien‐Hung</creatorcontrib><creatorcontrib>Tung, Hung‐Da</creatorcontrib><creatorcontrib>Chen, Tsung‐Ming</creatorcontrib><creatorcontrib>Huang, Wu‐Shiung</creatorcontrib><creatorcontrib>Lee, Chuan‐Mo</creatorcontrib><creatorcontrib>Chen, Chia‐Cheng</creatorcontrib><creatorcontrib>Changchien, Chi‐Sin</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lu, Sheng‐Nan</au><au>Wang, Jing‐Houng</au><au>Liu, Shiann‐Long</au><au>Hung, Chao‐Hung</au><au>Chen, Chien‐Hung</au><au>Tung, Hung‐Da</au><au>Chen, Tsung‐Ming</au><au>Huang, Wu‐Shiung</au><au>Lee, Chuan‐Mo</au><au>Chen, Chia‐Cheng</au><au>Changchien, Chi‐Sin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high‐risk for hepatocellular carcinoma</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2006-11-01</date><risdate>2006</risdate><volume>107</volume><issue>9</issue><spage>2212</spage><epage>2222</epage><pages>2212-2222</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND.
The objective of this study was to examine the usefulness of platelet counts in the diagnosis of cirrhosis and for identifying high‐risk individuals in a community‐based hepatocellular carcinoma (HCC) screening program.
METHODS.
Pilot Study 1 determined the correlation between platelet counts and pathologic hepatic fibrosis scores among individuals with chronic hepatitis B virus (HBV) infection (n = 122 patients) and hepatitis C virus (HCV) infection (n = 244 patients). Pilot Study 2 investigated proportions of individuals with thrombocytopenia (<150 × 103/mm3) among patients with HCC (n = 4042 patients). Pilot Study 3 demonstrated the correlation between platelet counts and ultrasonographic (US) parenchyma scores among anti‐HCV‐positive individuals (n = 75 patients). The core study was a 2‐stage, community‐based screening for HCC among residents age 40 years or older in townships with a high prevalence of anti‐HCV (n = 4616 individuals) and in townships with a low prevalence of anti‐HCV (n = 1694 individuals). Patients with thrombocytopenia were identified for US and α‐fetoprotein screening.
RESULTS.
Among the individuals who were positive for anti‐HCV, platelet counts decreased according to increased pathologic fibrosis scores or US scores for liver parenchyma disease: The best cutoff platelet count was 150 × 103/mm3 for a diagnosis of cirrhosis. The sensitivity and specificity were 68.2% and 76.4%, respectively, for pathologic cirrhosis and 76.2% and 87.8%, respectively, for US cirrhosis. Forty‐eight percent of patients with HCC were thrombocytopenic. The proportion of thrombocytopenia was significantly greater in patients with HCV‐related HCC (63%) than in patients with HBV‐related HCC (42%). In the townships with high and low anti‐HCV prevalence, the prevalence of thrombocytopenia was 17.9% and 6.1%, respectively, (P < .001), respectively. Twenty‐five patients were diagnosed with HCC, and all of those patients resided in the high‐prevalence township.
CONCLUSIONS.
Thrombocytopenia was a valid surrogate of cirrhosis and a valid marker for the identification of individuals at high‐risk for HCC, especially in areas that had a high prevalence of HCV. Cancer 2006. © 2006 American Cancer Society.
Thrombocytopenia is a valid surrogate of cirrhosis and is a marker for the identification of high‐risk patients with hepatocellular carcinoma, especially in areas with prevalent high hepatitis C virus infection.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>17019738</pmid><doi>10.1002/cncr.22242</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2006-11, Vol.107 (9), p.2212-2222 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69007224 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adult Aged Area Under Curve Biological and medical sciences Blood Platelets - pathology Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - epidemiology cirrhosis Community Health Services community screening Comorbidity Female Fibrosis - diagnosis Fibrosis - epidemiology Hematologic and hematopoietic diseases Hepatitis B - diagnosis Hepatitis B - epidemiology hepatitis B virus Hepatitis C - diagnosis Hepatitis C - epidemiology hepatitis C virus hepatocellular carcinoma Humans Liver Cirrhosis - diagnosis Liver Cirrhosis - epidemiology Liver Neoplasms - diagnosis Liver Neoplasms - epidemiology Male Mass Screening Medical sciences Middle Aged Pilot Projects platelet Platelet diseases and coagulopathies Predictive Value of Tests Prevalence Risk Factors Sensitivity and Specificity Survival Rate Taiwan - epidemiology Thrombocytopenia - diagnosis Thrombocytopenia - epidemiology Tumors ultrasonography α‐fetoprotein |
| title | Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high‐risk for hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T22%3A18%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thrombocytopenia%20as%20a%20surrogate%20for%20cirrhosis%20and%20a%20marker%20for%20the%20identification%20of%20patients%20at%20high%E2%80%90risk%20for%20hepatocellular%20carcinoma&rft.jtitle=Cancer&rft.au=Lu,%20Sheng%E2%80%90Nan&rft.date=2006-11-01&rft.volume=107&rft.issue=9&rft.spage=2212&rft.epage=2222&rft.pages=2212-2222&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.22242&rft_dat=%3Cproquest_cross%3E69007224%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69007224&rft_id=info:pmid/17019738&rfr_iscdi=true |